Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹10.54 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹10.54 Cr |
| Fresh Issue | ₹9.96 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹32.00-34.00 per share |
| Discount | Retail: 0.00 |
| NSE Code | MEDIORG |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | GYR Capital Advisors Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 4,000 shares and in multiples thereof
Medicamen Organics Limited was incorporated in 1995 and develops, manufactures, and distributes pharmaceutical dosages including generic dosages in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions and dry powders for the Government (including State Governments and Central Governments) and private entities as a contract manufacturer/third party manufacturer.
The company's product list comprises 84 products and offers a wide range of drugs such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral and non-steroidal anti-inflammatory drugs (NSAIDS).
The company's products are marketed throughout India as well as in African, CIS, and South East Asian countries such as Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya through third-party distributors.
The company has two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, covering an area of 21,536 Sq. Ft. As on September 30, 2023, the company has entered into contract manufacturing with 38 domestic partners and 12 merchant exporters.
As of September 30, 2023, the company employed a total of 116 people.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding of expenses proposed to be incurred towards Product registration in the international markets | 3.00 |
| 2 | Plant updation and increase in production capacity | 2.25 |
| 3 | Funding working capital requirements of our Company | 4.00 |
| 4 | General corporate purpose | 0.39 |
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 38.58 | 32.12 | 27.07 | 26.34 |
| Total Income | 25.29 | 22.96 | 21.19 | 25.06 |
| Profit After Tax | 2.40 | 0.96 | 0.09 | 0.30 |
| NET Worth | 15.18 | 8.52 | 7.56 | 7.47 |
| Reserves and Surplus | 6.58 | 2.52 | 1.56 | 1.47 |
| Total Borrowing | 12.66 | 11.80 | 10.25 | 9.59 |
| Amount in ₹ Crore | ||||
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 19.90% |
| ROCE | 14.50% |
| Debt / Equity | 0.83% |
| RoNW | 15.83% |
| PAT Margin | 9.51% |
| Price to Book Value | 2.39 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 1.11 | 2.21 |
| P/E (x) | 30.53 | 15.41 |
| Promoter Holding | 81.21% | |
| Market Cap | ₹39.78 Cr. | |
